Home
OverviewAbout10 LeapsCollaborationImpact
OverviewLeaps TalksChapter FilmsLeaps.orgPartners
AgricultureHealth
OverviewAnnual ReviewBreakthrough StudyPress ReleasesIn the NewsReportsLeaps LeadershipPress KitMedia Contact
Team
  • Approach
    • Overview
    • About
    • 10 Leaps
    • Collaboration
    • Impact
  • Engagement
    • Overview
    • Leaps Talks
    • Chapter Films
    • Leaps.org
    • Partners
    • Agriculture
    • Health
  • News
    • Overview
    • Annual Review
    • Breakthrough Study
    • Press Releases
    • In the News
    • Reports
    • Leaps Leadership
    • Press Kit
    • Media Contact
  • Team
ContactImprintPrivacy StatementConditions of Use
sign up for our newsletter
see more companies

Pyxis Oncology

pyxis oncology logo

Approach

Pyxis Oncology develops antibody therapeutics to promote the body‘s immune response to cancer. Leveraging new insights into the tumor microenvironment, Pyxis works to enhance the immune response against cancer—even in tumor types that historically have not responded well to cancer immunotherapies.

Pyxis (PYXS) went public in October 2021

Pyxis Oncology is addressing

  • Leap 04 / Prevent and cure cancer

CEO:

Lara Sullivan, MD

Founders:

David Steinberg

Shaan Gandhi (MD, DPhil)

John Flavin

First investment:

July 2019

www.pyxisoncology.com